The first 60 days: Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms
Histiocytoses are diseases in which immune scavenger cells build up in bone, heart, brain, kidneys and skin. They used to be treated as inflammatory conditions with steroids and interferon. The discovery that most carry mutations in the same growth pathway as melanoma turned them into targetable cancers: BRAF and MEK inhibitor pills now produce responses in nearly every treated patient. Below, week by week, is what OnCo's record of Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- SurgeonNamed in the standard of care for: Rosai-Dorfman disease.
- Medical oncologistNamed in the standard of care for: ECD, BRAF V600E-mutant, needing treatment, ECD or RDD, BRAF wild-type or intolerant of BRAF inhibitors, Rosai-Dorfman disease, Histiocytic sarcoma.
- Clinical oncologist (radiotherapy)Named in the standard of care for: Histiocytic sarcoma.
- Transplant and cell therapy teamNamed in the standard of care for: Histiocytic sarcoma.
- Palliative and supportive care teamNamed in the standard of care for: Histiocytic sarcoma.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Vemurafenib (FDA approval 2017) or dabrafenib, often with a MEK inhibitor to reduce toxicity; long-term treatment at the lowest effective dose.
Observation for asymptomatic nodal disease; surgery for isolated masses; steroids, sirolimus, cladribine or MEK inhibitors for symptomatic or multifocal disease.
Lymphoma-type chemotherapy (CHOP, ICE, or similar), radiotherapy for localised disease, MAPK-pathway inhibitors where mutations are found; clinical trials.
- 4.ECD or RDD, BRAF wild-type or intolerant of BRAF inhibitorsNCCN category Category 2A, NCCN Guidelines: Histiocytic Neoplasms
Cobimetinib (FDA approval October 2022 for histiocytic neoplasms) or another MEK inhibitor; interferon alfa or pegylated interferon as an alternative.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example BRAF V600E, MAP2K1, ARAF, NRAS, KRAS, PIK3CA, RAF1 and ALK fusions on NGS, Immunophenotype: CD68, CD163, factor XIIIa positive; CD1a and langerin negative; S100 with emperipolesis, FDG-PET/CT for extent and response, Cardiac MRI and brain MRI for organ involvement), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include Erdheim-Chester disease, Mixed ECD-LCH, Rosai-Dorfman-Destombes disease.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
ECD, BRAF V600E-mutant, needing treatment
- For my situation (ecd, braf v600e-mutant, needing treatment), which of the standard options do you recommend and why?Guideline options include: Vemurafenib (FDA approval 2017) or dabrafenib, often with a MEK inhibitor to reduce toxicity; long-term treatment at the lowest effective dose.
- Am I a candidate for Vemurafenib, Dabrafenib + trametinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
ECD or RDD, BRAF wild-type or intolerant of BRAF inhibitors
- For my situation (ecd or rdd, braf wild-type or intolerant of braf inhibitors), which of the standard options do you recommend and why?Guideline options include: Cobimetinib (FDA approval October 2022 for histiocytic neoplasms) or another MEK inhibitor; interferon alfa or pegylated interferon as an alternative.
- Am I a candidate for Cobimetinib, Interferon alfa-2a/2b, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Rosai-Dorfman disease
- For my situation (rosai-dorfman disease), which of the standard options do you recommend and why?Guideline options include: Observation for asymptomatic nodal disease; surgery for isolated masses; steroids, sirolimus, cladribine or MEK inhibitors for symptomatic or multifocal disease.
- Am I a candidate for Cladribine, Cobimetinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Histiocytic sarcoma
- For my situation (histiocytic sarcoma), which of the standard options do you recommend and why?Guideline options include: Lymphoma-type chemotherapy (CHOP, ICE, or similar), radiotherapy for localised disease, MAPK-pathway inhibitors where mutations are found; clinical trials.
- Am I a candidate for Cyclophosphamide, Doxorubicin, Etoposide or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of Cobimetinib, Vemurafenib, Dabrafenib + trametinib?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Most patients relapse when BRAF or MEK inhibitors stop; intermittent dosing and ctDNA-guided discontinuation are being tested”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Neurodegenerative ECD and LCH do not reverse with targeted therapy; earlier treatment and neuroprotective trials are the response”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms: the full pageHistiocytoses are diseases in which immune scavenger cells build up in bone, heart, brain, kidneys and skin. They used to be treated as inflammatory conditions with steroids and interferon. The discovery that most carry mutations in the same growth pathway as melanoma turned them into targetable cancers: BRAF and MEK inhibitor pills now produce responses in nearly every treated patient.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Driver mutation: One of the few mutations in a tumour that actually causes it to grow.
- BRAF V600E mutation: A single spelling change in the BRAF gene that jams a growth switch permanently on.
- Circulating tumour DNA (ctDNA): Circulating tumour DNA (ctDNA) consists of fragments of DNA shed by tumour cells into the blood, detectable with sensitive sequencing.
- Retroperitoneum: The space at the back of the abdomen, behind the gut's lining, holding the kidneys, adrenals, pancreas, aorta and the para-aortic lymph nodes.
Every term links to the glossary.